Sept 9 (Reuters) - Pharmaceutical giant AbbVie (ABBV.N), opens new tab has sued cancer treatment maker BeiGene (6160.HK), opens new tab in Chicago federal court, accusing it of stealing trade ...

In a lawsuit filed Friday, lawyers for AbbVie argued that BeiGene “enticed and encouraged” former AbbVie scientist Huaqing Liu, who’s named as a defendant in the case, to jump ship and share ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...

The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena Williams that went out of bounds with claims about how quickly the product ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study. In the Phase 3 ...

AbbVie's nonprofit foundation is partnering with health care incubator Matter on a new accelerator to advance solutions to improve care for underserved communities. The AbbVie Foundation Health ...

Local pharmaceutical giant AbbVie is suing drug manufacturer BeiGene over allegedly stealing trade secrets to develop a competing cancer drug following the hiring of a longtime AbbVie research ...

AbbVie (ABBV) closed the latest trading day at $196.42, indicating a +1.56% change from the previous session's end. This change outpaced the S&P 500's 1.16% gain on the day. Elsewhere, the Dow saw ...

AbbVie plans to present the full results at medical conferences and expects additional trial data from TEMPO-2 by the end of 2024. Tavapadon is an investigational D1/D5 dopamine receptor partial ...